-
President of Medicine & Science calls for unifying biomedical science and social determinants of care
A. Enrique Caballero, MD, highlighted the progress advancing diabetes treatment and management while shedding light on existing gaps in care and advocating for integrating advances in science into the real-world context in which people live.
-
Banting Medalist encourages embracing the unexpected to drive medical innovation
In his award lecture, Takashi Kadowaki, MD, PhD, explained how contradictions between hypotheses and results have enabled him to achieve major breakthroughs in understanding type 2 diabetes.
-
ADA President, Healthcare & Education highlights power and future potential of diabetes education and support
Amy Hess-Fischl, MS, RD, LDN, BC-ADM, CDCES, touted the success of diabetes self-management education and support (DSMES) programs and outlined steps to build on proven strengths. Saturday’s special session also included this year’s Distinguished International Service in the Cause of Diabetes Award Lecture.
-
Positive data from multiple amylin trials draw focus to novel therapeutic mechanism
Investigators, including Carel le Roux, MBChB, FRCP, FRCPath, PhD, discussed findings from monotherapy and combination trials with the pancreatic beta cell hormone. “Not only are these weight loss drugs, these are also health-gain drugs,” Dr. le Roux said.
-
Ultra-long-acting GLP-1 RA improves weight loss in individuals with and without type 2 diabetes
A Scientific Sessions panel shared new data from the VESPER trials. The long half-life of berobenatide makes investigators optimistic about its potential for monthly dosing.